Q: I was hospitalized for the first time in 2007, when I had glutamic oxalacetic transaminase 64 and glutamic alanine transaminase 70, and the virus was not replicating. After 40 days of hepatoprotective treatment, all indicators were normal. In June 2013, I was hospitalized for the second time, with 110 GTR, 90 ALTR, 3*10 of five times viral replication, and all indicators were normal after 30 days of liver-protective treatment. I would like to ask you: if I am only on hepatoprotective treatment, is it okay to not use interferon because it has a lot of side effects? If I have to take antiviral treatment, which one is more effective, interferon or nucleosides? A: Your question is also very common, the answer is as follows: 1. For patients with small triplets of hepatitis B, repeated abnormal liver function, HBV DNA below the 5th power of 10, you need to consider antiviral therapy. Because patients with minor triplets belong to the late stage of the natural history of chronic hepatitis B, most of them go through the carrier phase, clearance phase and finally enter the relapse phase, where the liver reserve function decreases and liver fibrosis is heavy, thus antiviral treatment as soon as possible can effectively stop the occurrence of cirrhosis. 2, for this type of patients if you choose antiviral treatment, is it nucleoside or interferon therapy? This requires the clinician’s experience and level. From the current expert consensus and clinical research results; small triplet interferon treatment, past research relapse rate of about 50-70%, but these are mostly foreign data, especially genotype D patients with poor efficacy, but our data show that long-acting interferon still has good efficacy, but the course of treatment requires more than 1.5 years, the relapse rate will be greatly reduced, and currently Roche is conducting related research in China. And according to our clinical research, about 15% of patients with small triplets can show the disappearance of HBsAg after treatment, but the quantitative HBsAg test is needed before treatment, and the rate of HBsAg conversion is higher for patients with HBsAg quantification less than 1000 or even 200. And nucleoside analogues are the most commonly used regimen for the treatment of small triplets, but for small triplet patients once the nucleoside analogues are used, it is not possible to stop the drug, such as a study of entecavir, small triplet patients treated for 5 years, stopping the drug has 95% of patients relapse. 3, for patients with low liver fibrosis (such as has been inactive carriers relapse) can use liver preservation therapy, as well as combined with traditional Chinese medicine, we clinically found that some patients can appear viral clearance, to achieve treatment goals. This is because nucleoside drug therapy does not clear cccDNA, which means it does not clear the virus, but only inhibits it. Thus, as long as the liver is protected from cirrhosis, which is the goal of our treatment. In conclusion, the choice of treatment option needs to be made in relation to the goal of treatment.